These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 1350228)

  • 21. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis.
    Sanchorawala V; Wright DG; Seldin DC; Dember LM; Finn K; Falk RH; Berk J; Quillen K; Skinner M
    Bone Marrow Transplant; 2001 Oct; 28(7):637-42. PubMed ID: 11704785
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
    Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
    Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Autologous bone marrow transplantation contributes to haemopoietic recovery in children with solid tumours treated with high dose melphalan.
    Kingston JE; Malpas JS; Stiller CA; Pritchard J; McElwain TJ
    Br J Haematol; 1984 Dec; 58(4):589-95. PubMed ID: 6394042
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety of autologous hematopoietic stem cell transplantation in patients with multiple myeloma and chronic renal failure.
    Tosi P; Zamagni E; Ronconi S; Benni M; Motta MR; Rizzi S; Tura S; Cavo M
    Leukemia; 2000 Jul; 14(7):1310-3. PubMed ID: 10914557
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Induction therapy with vincristine, adriamycin, dexamethasone (VAD) and intermediate-dose melphalan (IDM) followed by autologous or allogeneic stem cell transplantation in newly diagnosed multiple myeloma.
    Lokhorst HM; Sonneveld P; Cornelissen JJ; Joosten P; van Marwijk Kooy M; Meinema J; Nieuwenhuis HK; van Oers MH; Richel DJ; Segeren CN; Veth G; Verdonck LF; Wijermans PW
    Bone Marrow Transplant; 1999 Feb; 23(4):317-22. PubMed ID: 10100574
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High melphalan exposure is associated with improved overall survival in myeloma patients receiving high dose melphalan and autologous transplantation.
    Nath CE; Trotman J; Tiley C; Presgrave P; Joshua D; Kerridge I; Kwan YL; Gurney H; McLachlan AJ; Earl JW; Nivison-Smith I; Zeng L; Shaw PJ
    Br J Clin Pharmacol; 2016 Jul; 82(1):149-59. PubMed ID: 26879446
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of chemotherapy on the mobilisation, harvest and economic costs of autologous peripheral stem cell transplantation in patients with multiple myeloma.
    Jerjis S; Croockewit S; Preijers F; Schaap N; De Witte T
    Leuk Lymphoma; 2000 May; 37(5-6):551-60. PubMed ID: 11042515
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Phase I Trial of High-Dose Lenalidomide and Melphalan as Conditioning for Autologous Stem Cell Transplantation in Relapsed or Refractory Multiple Myeloma.
    Mark TM; Guarneri D; Forsberg P; Rossi A; Pearse R; Perry A; Pekle K; Tegnestam L; Greenberg J; Shore T; Gergis U; Mayer S; Van Besien K; Ely S; Jayabalan D; Sherbenou D; Coleman M; Niesvizky R
    Biol Blood Marrow Transplant; 2017 Jun; 23(6):930-937. PubMed ID: 28285081
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Upfront autologous stem cell transplantation for newly diagnosed elderly multiple myeloma patients: a prospective multicenter study.
    Garderet L; Beohou E; Caillot D; Stoppa AM; Touzeau C; Chretien ML; Karlin L; Moreau P; Fontan J; Blaise D; Polge E; Gueye MS; Ikhlef S; Marjanovic Z; Labopin M; Mohty M
    Haematologica; 2016 Nov; 101(11):1390-1397. PubMed ID: 27612987
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The choice of multiple myeloma induction therapy affects the frequency and severity of oral mucositis after melphalan-based autologous stem cell transplantation.
    Fleming S; Harrison SJ; Blombery P; Joyce T; Stokes K; Seymour JF; Prince HM; Ritchie D
    Clin Lymphoma Myeloma Leuk; 2014 Aug; 14(4):291-6. PubMed ID: 24629850
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [First-line treatment of severe myelomas of the young subject by high-dose melphalan].
    Harousseau JL; Milpied N; Guilhot F; Garand R; Bourhis JH
    Presse Med; 1988 Aug 27-Sep 3; 17(29):1471-4. PubMed ID: 2971190
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Melphalan 200 mg/m(2) versus melphalan 100 mg/m(2) in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study.
    Palumbo A; Bringhen S; Bruno B; Falcone AP; Liberati AM; Grasso M; Ria R; Pisani F; Cangialosi C; Caravita T; Levi A; Meloni G; Nozza A; Pregno P; Gabbas A; Callea V; Rizzo M; Annino L; De Stefano V; Musto P; Baldi I; Cavallo F; Petrucci MT; Massaia M; Boccadoro M
    Blood; 2010 Mar; 115(10):1873-9. PubMed ID: 19965659
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of autologous transplantation in patients with multiple myeloma aged 65 years and over.
    Sirohi B; Powles R; Treleaven J; Mainwaring P; Kulkarni S; Pandha H; Bhagwati N; Horton C; Singhal S; Mehta J
    Bone Marrow Transplant; 2000 Mar; 25(5):533-9. PubMed ID: 10713631
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase I-II evaluation of rapid sequence tandem high-dose melphalan with peripheral blood stem cell support in patients with multiple myeloma.
    Weaver CH; Zhen B; Schwartzberg LS; Leff R; Magee M; Geier L; Deaton K; Lewkow L; Buckner CD
    Bone Marrow Transplant; 1998 Aug; 22(3):245-51. PubMed ID: 9720737
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM).
    Roussel M; Moreau P; Huynh A; Mary JY; Danho C; Caillot D; Hulin C; Fruchart C; Marit G; Pégourié B; Lenain P; Araujo C; Kolb B; Randriamalala E; Royer B; Stoppa AM; Dib M; Dorvaux V; Garderet L; Mathiot C; Avet-Loiseau H; Harousseau JL; Attal M;
    Blood; 2010 Jan; 115(1):32-7. PubMed ID: 19884643
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Repeat administration of high dose melphalan in relapsed myeloma.
    Mansi JL; Cunningham D; Viner C; Ellis E; Meldrum M; Milan S; Gore M
    Br J Cancer; 1993 Nov; 68(5):983-7. PubMed ID: 8217614
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High dose melphalan or intermediate dose melphalan can be well tolerated and result in good response rates in selected elderly patients with myeloma.
    Bishton M; Gilyead M; Das Gupta E; Williams C; Russell NH; Byrne JL
    Leuk Res; 2007 Aug; 31(8):1063-8. PubMed ID: 17324463
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Autologous stem cell transplantation in first remission is associated with better progression-free survival in multiple myeloma.
    Aggarwal M; Agrawal N; Yadav N; Verma P; Ahmed R; Mehta P; Kapoor J; Bhurani D
    Ann Hematol; 2018 Oct; 97(10):1869-1877. PubMed ID: 29781040
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of autologous bone marrow transplantation and peripheral blood stem cell transplantation after first remission induction treatment in multiple myeloma.
    Harousseau JL; Attal M; Divine M; Milpied N; Marit G; Leblond V; Stoppa AM; Bourhis JH; Caillot D; Boasson M
    Bone Marrow Transplant; 1995 Jun; 15(6):963-9. PubMed ID: 7581098
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Results of a phase I/II trial adding carmustine (300 mg/m2) to melphalan (200 mg/m2) in multiple myeloma patients undergoing autologous stem cell transplantation.
    Comenzo RL; Hassoun H; Kewalramani T; Klimek V; Dhodapkar M; Reich L; Teruya-Feldstein J; Fleisher M; Filippa D; Nimer SD
    Leukemia; 2006 Feb; 20(2):345-9. PubMed ID: 16319952
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.